{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T05:32:34Z","timestamp":1795066354705,"version":"4.10.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with locally-advanced non-small-cell lung cancer (LA-NSCLC) are often ineligible for surgery, so that definitive chemoradiotherapy (CRT) represents the treatment of choice. Nevertheless, long-term tumor control is often not achieved. Intensification of radiotherapy (RT) to improve locoregional tumor control is limited by the detrimental effect of higher radiation exposure of thoracic organs-at-risk (OAR). This narrow therapeutic ratio may be expanded by exploiting the advantages of magnetic resonance (MR) linear accelerators, mainly the online adaptation of the treatment plan to the current anatomy based on daily acquired MR images. However, MR-guidance is both labor-intensive and increases treatment times, which raises the question of its clinical feasibility to treat LA-NSCLC. Therefore, the PUMA trial was designed as a prospective, multicenter phase I trial to demonstrate the clinical feasibility of MR-guided online adaptive RT in LA-NSCLC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Thirty patients with LA-NSCLC in stage III A-C will be accrued at three German university hospitals to receive MR-guided online adaptive RT at two different MR-linac systems (MRIdian Linac\u00ae, View Ray Inc. and Elekta Unity\u00ae, Elekta AB) with concurrent chemotherapy. Conventionally fractioned RT with isotoxic dose escalation up to 70\u00a0Gy is applied. Online plan adaptation is performed once weekly or in case of major anatomical changes. Patients are followed-up by thoracic CT- and MR-imaging for 24 months after treatment. The primary endpoint is twofold: (1) successfully completed online adapted fractions, (2) on-table time. Main secondary endpoints include adaptation frequency, toxicity, local tumor control, progression-free and overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>PUMA aims to demonstrate the clinical feasibility of MR-guided online adaptive RT of LA-NSCLC. If successful, PUMA will be followed by a clinical phase II trial that further investigates the clinical benefits of this approach. Moreover, PUMA is part of a large multidisciplinary project to develop MR-guidance techniques.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>ClinicalTrials.gov:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05237453\">NCT05237453<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13014-023-02258-9","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T15:01:52Z","timestamp":1683212512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced non-small-cell lung cancer: the PUMA trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Sebastian","family":"Regnery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"de Colle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwuka","family":"Eze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thieke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sedlaczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Peter","family":"Schlemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Dinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand","family":"Seith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Kopp-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Gillmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Katharina","family":"Renkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Landry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Thorwarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"J\u00e4kel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"issue":"20","key":"2258_CR1","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"4","key":"2258_CR2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/JTO.0b013e3182429682","volume":"7","author":"M Machtay","year":"2012","unstructured":"Machtay M, Paulus R, Moughan J, Komaki R, Bradley JE, Choy H, et al. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol. 2012;7(4):716\u201322.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2258_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.radonc.2016.02.008","volume":"118","author":"JN van Diessen","year":"2016","unstructured":"van Diessen JN, Chen C, van den Heuvel MM, Belderbos JS, Sonke JJ. Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy. Radiother Oncol. 2016;118(3):447\u201352.","journal-title":"Radiother Oncol"},{"issue":"6","key":"2258_CR4","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.21873\/anticanres.14339","volume":"40","author":"T Abe","year":"2020","unstructured":"Abe T, Kobayashi N, Aoshika T, Ryuno Y, Saito S, Igari M, et al. Pattern of local failure and its risk factors of locally advanced non-small cell lung Cancer treated with concurrent chemo-radiotherapy. Anticancer Res. 2020;40(6):3513\u20137.","journal-title":"Anticancer Res"},{"issue":"1","key":"2258_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13014-020-01590-8","volume":"15","author":"J Taugner","year":"2020","unstructured":"Taugner J, Eze C, K\u00e4smann L, Roengvoraphoj O, Gennen K, Karin M, et al. Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer. Radiat Oncol. 2020;15(1):148.","journal-title":"Radiat Oncol"},{"issue":"19","key":"2258_CR6","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/jnci\/djr325","volume":"103","author":"WJ Curran Jr","year":"2011","unstructured":"Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452\u201360.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2258_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0360-3016(00)01374-2","volume":"49","author":"M Mehta","year":"2001","unstructured":"Mehta M, Scrimger R, Mackie R, Paliwal B, Chappell R, Fowler J. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2001;49(1):23\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2258_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ijrobp.2010.09.004","volume":"82","author":"M Machtay","year":"2012","unstructured":"Machtay M, Bae K, Movsas B, Paulus R, Gore EM, Komaki R, et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2012;82(1):425\u201334.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"2258_CR9","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/annonc\/mdw276","volume":"27","author":"JV Brower","year":"2016","unstructured":"Brower JV, Amini A, Chen S, Hullett CR, Kimple RJ, Wojcieszynski AP, et al. Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database. Ann Oncol. 2016;27(10):1887\u201394.","journal-title":"Ann Oncol"},{"issue":"1","key":"2258_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijrobp.2008.06.1939","volume":"74","author":"M Guckenberger","year":"2009","unstructured":"Guckenberger M, Wulf J, Mueller G, Krieger T, Baier K, Gabor M, et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys. 2009;74(1):47\u201354.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2258_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"JD Bradley","year":"2015","unstructured":"Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187\u201399.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2258_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.radonc.2016.04.025","volume":"119","author":"SL Tucker","year":"2016","unstructured":"Tucker SL, Liu A, Gomez D, Tang LL, Allen P, Yang J, et al. Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. Radiother Oncol. 2016;119(3):495\u2013500.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2258_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","volume":"35","author":"SG Chun","year":"2017","unstructured":"Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, et al. Impact of intensity-modulated Radiation Therapy technique for locally Advanced Non-Small-Cell Lung Cancer: a secondary analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol. 2017;35(1):56\u201362.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2258_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jtho.2016.09.134","volume":"12","author":"CK Speirs","year":"2017","unstructured":"Speirs CK, DeWees TA, Rehman S, Molotievschi A, Velez MA, Mullen D, et al. Heart dose is an independent dosimetric predictor of overall survival in locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(2):293\u2013301.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2258_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ijrobp.2006.03.064","volume":"66","author":"ML Siker","year":"2006","unstructured":"Siker ML, Tom\u00e9 WA, Mehta MP. Tumor volume changes on serial imaging with megavoltage CT for non-small-cell lung cancer during intensity-modulated radiotherapy: how reliable, consistent, and meaningful is the effect? Int J Radiat Oncol Biol Phys. 2006;66(1):135\u201341.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2258_CR16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.radonc.2014.10.009","volume":"113","author":"M Kwint","year":"2014","unstructured":"Kwint M, Conijn S, Schaake E, Knegjens J, Rossi M, Remeijer P, et al. Intra thoracic anatomical changes in lung cancer patients during the course of radiotherapy. Radiother Oncol. 2014;113(3):392\u20137.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2258_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.radonc.2016.08.019","volume":"121","author":"DS M\u00f8ller","year":"2016","unstructured":"M\u00f8ller DS, Holt MI, Alber M, Tvilum M, Khalil AA, Knap MM, et al. Adaptive radiotherapy for advanced lung cancer ensures target coverage and decreases lung dose. Radiother Oncol. 2016;121(1):32\u20138.","journal-title":"Radiother Oncol"},{"issue":"10","key":"2258_CR18","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jamaoncol.2017.0982","volume":"3","author":"FM Kong","year":"2017","unstructured":"Kong FM, Ten Haken RK, Schipper M, Frey KA, Hayman J, Gross M, et al. Effect of Midtreatment PET\/CT-Adapted Radiation Therapy with concurrent chemotherapy in patients with locally Advanced Non-Small-Cell Lung Cancer: a phase 2 clinical trial. JAMA Oncol. 2017;3(10):1358\u201365.","journal-title":"JAMA Oncol"},{"key":"2258_CR19","doi-asserted-by":"publisher","first-page":"564857","DOI":"10.3389\/fonc.2020.564857","volume":"10","author":"P Hoegen","year":"2020","unstructured":"Hoegen P, Lang C, Akbaba S, H\u00e4ring P, Splinter M, Miltner A, et al. Cone-Beam-CT guided adaptive Radiotherapy for locally Advanced Non-small Cell Lung Cancer enables Quality Assurance and Superior Sparing of healthy lung. Front Oncol. 2020;10:564857.","journal-title":"Front Oncol"},{"key":"2258_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.radonc.2021.02.019","volume":"158","author":"Y Meng","year":"2021","unstructured":"Meng Y, Luo W, Xu H, Wang W, Zhou S, Tang X, et al. Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: is a routine adaptation beneficial? Radiother Oncol. 2021;158:118\u201324.","journal-title":"Radiother Oncol"},{"issue":"7","key":"2258_CR21","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jtho.2017.03.025","volume":"12","author":"S Ramella","year":"2017","unstructured":"Ramella S, Fiore M, Silipigni S, Zappa MC, Jaus M, Alberti AM, et al. Local control and toxicity of adaptive Radiotherapy using Weekly CT Imaging: results from the LARTIA Trial in Stage III NSCLC. J Thorac Oncol. 2017;12(7):1122\u201330.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2258_CR22","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1016\/j.ijrobp.2011.01.067","volume":"81","author":"M Guckenberger","year":"2011","unstructured":"Guckenberger M, Richter A, Wilbert J, Flentje M, Partridge M. Adaptive radiotherapy for locally advanced non-small-cell lung cancer does not underdose the microscopic disease and has the potential to increase tumor control. Int J Radiat Oncol Biol Phys. 2011;81(4):e275\u201382.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2258_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.clon.2018.08.003","volume":"30","author":"GP Liney","year":"2018","unstructured":"Liney GP, Whelan B, Oborn B, Barton M, Keall P. MRI-Linear Accelerator Radiotherapy Systems. Clin Oncol (R Coll Radiol). 2018;30(11):686\u201391.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2258_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ctro.2019.04.007","volume":"18","author":"S Kl\u00fcter","year":"2019","unstructured":"Kl\u00fcter S. Technical design and concept of a 0.35 T MR-Linac. Clin translational radiation Oncol. 2019;18:98\u2013101.","journal-title":"Clin translational radiation Oncol"},{"issue":"4","key":"2258_CR25","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ijrobp.2019.03.035","volume":"104","author":"T Finazzi","year":"2019","unstructured":"Finazzi T, Palacios MA, Spoelstra FOB, Haasbeek CJA, Bruynzeel AME, Slotman BJ, et al. Role of On-Table plan adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors. Int J Radiat Oncol Biol Phys. 2019;104(4):933\u201341.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2258_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ijrobp.2020.02.025","volume":"107","author":"T Finazzi","year":"2020","unstructured":"Finazzi T, Haasbeek CJA, Spoelstra FOB, Palacios MA, Admiraal MA, Bruynzeel AME, et al. Clinical outcomes of stereotactic MR-Guided adaptive Radiation Therapy for high-risk lung tumors. Int J Radiat Oncol Biol Phys. 2020;107(2):270\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2258_CR27","doi-asserted-by":"publisher","first-page":"757031","DOI":"10.3389\/fonc.2021.757031","volume":"11","author":"S Regnery","year":"2021","unstructured":"Regnery S, Buchele C, Weykamp F, Pohl M, Hoegen P, Eichkorn T, et al. Adaptive MR-Guided stereotactic Radiotherapy is beneficial for ablative treatment of lung tumors in high-risk locations. Front Oncol. 2021;11:757031.","journal-title":"Front Oncol"},{"issue":"2","key":"2258_CR28","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ijrobp.2005.01.032","volume":"62","author":"RW Underberg","year":"2005","unstructured":"Underberg RW, Lagerwaard FJ, Slotman BJ, Cuijpers JP, Senan S. Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: an analysis of 4DCT datasets. Int J Radiat Oncol Biol Phys. 2005;62(2):554\u201360.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2258_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.radonc.2019.10.013","volume":"144","author":"T Finazzi","year":"2020","unstructured":"Finazzi T, Palacios MA, Haasbeek CJA, Admiraal MA, Spoelstra FOB, Bruynzeel AME, et al. Stereotactic MR-guided adaptive radiation therapy for peripheral lung tumors. Radiother Oncol. 2020;144:46\u201352.","journal-title":"Radiother Oncol"},{"issue":"5","key":"2258_CR30","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.ijrobp.2017.11.009","volume":"101","author":"M van Herk","year":"2018","unstructured":"van Herk M, McWilliam A, Dubec M, Faivre-Finn C, Choudhury A. Magnetic resonance imaging-guided Radiation Therapy: a short Strengths, Weaknesses, Opportunities, and Threats Analysis. Int J Radiat Oncol Biol Phys. 2018;101(5):1057\u201360.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2258_CR31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","volume":"21","author":"U Nestle","year":"2020","unstructured":"Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, K\u00fcsters A, et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol. 2020;21(4):581\u201392.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2258_CR32","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/JTO.0b013e3181a0d82e","volume":"4","author":"VW Rusch","year":"2009","unstructured":"Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4(5):568\u201377.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2258_CR33","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.radonc.2017.07.028","volume":"125","author":"O Bohoudi","year":"2017","unstructured":"Bohoudi O, Bruynzeel AME, Senan S, Cuijpers JP, Slotman BJ, Lagerwaard FJ, et al. Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. Radiother Oncol. 2017;125(3):439\u201344.","journal-title":"Radiother Oncol"},{"key":"2258_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.radonc.2022.01.039","volume":"168","author":"DS M\u00f8ller","year":"2022","unstructured":"M\u00f8ller DS, Lutz CM, Khalil AA, Alber M, Holt MI, Kandi M, et al. Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy. Radiother Oncol. 2022;168:234\u201340.","journal-title":"Radiother Oncol"},{"issue":"2","key":"2258_CR35","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1148\/radiol.2020201138","volume":"297","author":"H Hatabu","year":"2020","unstructured":"Hatabu H, Ohno Y, Gefter WB, Parraga G, Madore B, Lee KS, et al. Expanding applications of pulmonary MRI in the clinical evaluation of Lung Disorders: Fleischner Society position paper. Radiology. 2020;297(2):286\u2013301.","journal-title":"Radiology"},{"issue":"1","key":"2258_CR36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.adro.2018.10.003","volume":"4","author":"LE Henke","year":"2019","unstructured":"Henke LE, Olsen JR, Contreras JA, Curcuru A, DeWees TA, Green OL, et al. Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: results of a phase 1 trial. Adv radiation Oncol. 2019;4(1):201\u20139.","journal-title":"Adv radiation Oncol"},{"issue":"12","key":"2258_CR37","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1097\/JTO.0b013e3182307ec2","volume":"6","author":"P Giraud","year":"2011","unstructured":"Giraud P, Morvan E, Claude L, Mornex F, Le Pechoux C, Bachaud JM, et al. Respiratory gating techniques for optimization of lung cancer radiotherapy. J Thorac Oncol. 2011;6(12):2058\u201368.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2258_CR38","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.radonc.2016.02.011","volume":"118","author":"I Walraven","year":"2016","unstructured":"Walraven I, van den Heuvel M, van Diessen J, Schaake E, Uyterlinde W, Aerts J, et al. Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. Radiother Oncol. 2016;118(3):442\u20136.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2258_CR39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/cncr.24732","volume":"116","author":"S Bral","year":"2010","unstructured":"Bral S, Duchateau M, Versmessen H, Verdries D, Engels B, De Ridder M, et al. Toxicity report of a phase 1\/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy. Cancer. 2010;116(1):241\u201350.","journal-title":"Cancer"},{"issue":"1","key":"2258_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijrobp.2018.01.046","volume":"101","author":"JJ Urbanic","year":"2018","unstructured":"Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, et al. Phase 1 study of Accelerated Hypofractionated Radiation Therapy with Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys. 2018;101(1):177\u201385.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2258_CR41","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.radonc.2020.04.033","volume":"148","author":"K Glinski","year":"2020","unstructured":"Glinski K, Socha J, Wasilewska-Tesluk E, Komosinska K, Kepka L. Accelerated hypofractionated radiotherapy with concurrent full dose chemotherapy for locally advanced non-small cell lung cancer: a phase I\/II study. Radiother Oncol. 2020;148:174\u201380.","journal-title":"Radiother Oncol"},{"key":"2258_CR42","unstructured":"Deutsche Leitlinienprogramm Onkologie DK. AWMF),. S3-Leitlinie Pr\u00e4vention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms Langversion 1.0. 2018 Februar 2018."},{"issue":"5","key":"2258_CR43","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.ijrobp.2020.11.040","volume":"109","author":"K Haslett","year":"2021","unstructured":"Haslett K, Bayman N, Franks K, Groom N, Harden SV, Harris C, et al. Isotoxic intensity modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2021;109(5):1341\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2258_CR44","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.radonc.2018.10.006","volume":"132","author":"FS Kong","year":"2019","unstructured":"Kong FS, Li L, Wang W, Campbell J, Waller JL, Piert M, et al. Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. Radiother Oncol. 2019;132:241\u20139.","journal-title":"Radiother Oncol"}],"updated-by":[{"DOI":"10.1186\/s13014-023-02294-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000}}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02258-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02258-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02258-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T02:40:50Z","timestamp":1702348850000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02258-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2258"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02258-9","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13014-023-02294-5","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"3 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13014-023-02294-5","URL":"https:\/\/doi.org\/10.1186\/s13014-023-02294-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PUMA trial was approved by the local ethics board of the Medical Faculty at Heidelberg University (coordinating trial center, IRB number: S-701\/2021) and by the local ethic boards at the trial centers in Munich and Tuebingen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J. H.-R. and S. K. received speaker fees from ViewRay Inc. J. H.-R. received speaker fees from Pfizer Inc., travel reimbursement from ViewRay Inc., IntraOP Medical and Elekta Instrument AB as well as grants from IntraOP Medical and Varian Medical Systems outside the submitted work. J.D. received grants from View Ray Inc., from CRI \u2013 The Clinical Research Institute GmbH, Accuray Incorporated, Accuray International S\u00e0rl, RaySearch Laboratories AB, Vision RT limited, Astellas Pharma GmbH, Astra Zeneca GmbH, Solution Akademie GmbH, Ergomed PLC Surrey Research Park, Merck Serono GmbH, Siemens Healthcare GmbH, Quintiles GmbH, Pharmaceutecal Research Associates GmbH, Boehringer Ingelheim Pharma GmbH Co, PTW-Freiburg Dr. Pychlau GmbH, Nanobiotix A.A. and IntraOP Medical outside the submitted work. Travel costs were covered by Elekta for C. G. C.B. and S.C. have received research grants and speaker fees\/travel support from Elekta, Viewray and Brainlab.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}